EmBioProMS
Explorative Study of Emerging Blood Biomarkers in Progressive Multiple Sclerosis
As the duration of the disease increases, the risk of developing progressive MS (PMS) grows. In this progressive phase, immunotherapies often begin to function worse and therapeutic goals need to be readjusted.
EUReMS
European MS Register
Improving Multiple Sclerosis Management in Europe: Better Outcomes with Better Data